---
title: "SBP GROUP: TQB3205 \"PAN-KRAS inhibitor\" clinical trial application approved by the FDA"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282106571.md"
description: "The subsidiary of China Biologic Products Holdings, Chengdu Kanghong Pharmaceutical Group, has independently developed TQB3205 \"Pan-KRAS inhibitor,\" which has been approved by the FDA for clinical trials. This drug is used for advanced malignant tumors and can efficiently bind to KRAS mutant proteins, locking them in an inactive state, thereby blocking related signaling pathways and effectively inhibiting tumor cell proliferation"
datetime: "2026-04-08T23:14:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282106571.md)
  - [en](https://longbridge.com/en/news/282106571.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282106571.md)
---

# SBP GROUP: TQB3205 "PAN-KRAS inhibitor" clinical trial application approved by the FDA

On the morning of April 9th, China Biologic Products Holdings announced on the Hong Kong Stock Exchange that its subsidiary, Chengdu Kanghong Pharmaceutical Group Co., Ltd. ("Kanghong"), has received approval from the U.S. Food and Drug Administration (FDA) for a new drug clinical trial (IND) for its independently developed innovative drug TQB3205, a "Pan-KRAS inhibitor," for advanced malignant tumors. TQB3205 capsules are an oral Pan-KRAS inhibitor that can bind with high affinity to various KRAS mutant proteins, locking the KRAS protein in an inactive state, thereby blocking downstream signaling pathways (such as the MAPK pathway and the PI3K-AKT pathway), ultimately effectively inhibiting the proliferation of various KRAS mutant tumor cells and precisely exerting anti-tumor effects at the target level

### Related Stocks

- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [002393.CN](https://longbridge.com/en/quote/002393.CN.md)

## Related News & Research

- [Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline](https://longbridge.com/en/news/286328735.md)
- [Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate | ONNVF Stock News](https://longbridge.com/en/news/286620198.md)
- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)
- [TransThera reports promising tinengotinib results in advanced solid tumors](https://longbridge.com/en/news/286670762.md)
- [Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade | PPCB Stock News](https://longbridge.com/en/news/287069272.md)